TRT(SH:600085)2014-03-24 16:00Financial Performance - The company achieved a net profit attributable to shareholders of RMB 656,013,728.53, representing a 15.08% increase compared to the previous year[4]. - Total operating revenue for the year was RMB 8,714,647,401.68, reflecting a year-on-year growth of 15.94%[16]. - The basic earnings per share increased to RMB 0.503, up 14.84% from RMB 0.438 in 2012[17]. - The company's total assets reached RMB 11,911,900,010.52, a 22.95% increase from the previous year[16]. - The net assets attributable to shareholders rose to RMB 5,017,972,105.22, marking a 26.09% increase year-on-year[16]. - Operating profit grew by 20.42% year-on-year, contributing to the achievement of annual operational goals[21]. - The company reported a decrease in the weighted average return on net assets to 14.91%, down 0.64 percentage points from the previous year[17]. - The company’s gross profit margin in the pharmaceutical industry decreased by 2.61 percentage points to 46.64%[35]. Cash Flow and Investments - Cash flow from operating activities was RMB 676,398,667.36, down 22.56% compared to the previous year[16]. - The company's investment activities generated a net cash flow of -431.43 million RMB, indicating increased capital expenditures[32]. - The company’s cash and cash equivalents increased by 1.247 billion RMB, despite a 20.07% decline in net increase compared to the previous year[33]. - The company reported a net cash flow from operating activities of RMB 676,398,667.36, down 22.56% to approximately ¥676.40 million[23]. - Cash inflow from financing activities amounted to RMB 2,012,132,724.83, significantly up from RMB 1,606,850,000.00 in 2012[143]. Research and Development - The company's research and development expenditure was approximately ¥48.68 million, reflecting a 14.94% increase compared to the previous year[23]. - The company successfully completed the second phase of clinical research for a new drug and initiated the third phase, indicating ongoing commitment to product development[25]. - The company is focusing on technological innovation and improving production efficiency to maintain profit levels[52]. Marketing and Sales - The company launched a new product, Ba Jitian Guo Tang Capsules, which has been preliminarily sold in 11 provinces, enhancing market presence[24]. - The company’s marketing strategy involved optimizing channel layouts and enhancing communication with distributors to improve sales efficiency[22]. - The sales policy of cash sales and clearing accounts receivable at the end of each quarter was maintained, ensuring quality in operations and asset management[24]. Shareholder and Dividend Information - The company plans to distribute a cash dividend of RMB 2.0 per 10 shares to all shareholders[4]. - In 2013, the net profit attributable to shareholders was 656,013,728.53 RMB, representing a profit distribution ratio of 39.97%[60]. - The company distributed a cash dividend of 2.5 RMB per 10 shares (including tax) for the 2012 fiscal year, approved at the 2012 annual general meeting[58]. Corporate Governance - The company has established a governance structure including a shareholders' meeting, board of directors, and supervisory board[159]. - The company maintains independence from its controlling shareholder in business, personnel, assets, and financial matters[121]. - The company has appointed independent directors with extensive backgrounds in the pharmaceutical industry, ensuring compliance and strategic oversight[95][96]. Risk Management - The company faces risks related to policy changes and raw material costs, necessitating flexible adjustments to market demands[55]. - The overall price trend of traditional Chinese medicine raw materials is upward, with increased demand from the foreign pharmaceutical industry leading to shortages of certain materials[56]. Employee and Management Information - The total number of employees in the parent company and major subsidiaries reached 12,948 as of December 31, 2013, with 2,509 in the parent company and 10,439 in subsidiaries[105]. - The company organized over 500 training sessions for employees, promoting mutual communication and enhancing corporate culture[107]. - The total amount of cash rewards distributed to senior management for 2012 performance was 3.225 million RMB (including tax)[102]. Audit and Compliance - The company has received a standard unqualified audit opinion for its 2013 financial report[57]. - The internal control audit conducted by the accounting firm yielded a standard unqualified opinion, confirming the effectiveness of the company's internal controls[126]. - The company has not faced any regulatory investigations or penalties from the China Securities Regulatory Commission during the reporting period[73].